Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank
May 14, 2024 4:12 PM EDTDeutsche Bank analyst James Shin lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $10.00 (from $12.00) while maintaining a Buy rating.
The analyst comments "We're updating our STRO model for 1Q24 results, maintaining our Buy rating and lowering our price target to... More
Wedbush Reiterates Outperform Rating on Sutro Biopharma (STRO)
May 14, 2024 8:25 AM EDTWedbush analyst David Nierengarten reiterated an Outperform rating and $8.00 price target on Sutro Biopharma (NASDAQ: STRO)
The analyst comments "STRO reported 1Q24 earnings. The company continues to advance lead asset luvelta (FolR-targeted ADC) through multiple clinical studies. Part 1 of the registration-directed REFRaME-01 study in... More
